This is general educational content. Personal health decisions should involve a qualified clinician familiar with your medical history.
What happens to skeletal muscle and bone when a patient loses weight faster than any natural mechanism intended? The glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide among them, produce remarkable reductions in body mass. But the composition of that lost mass worries clinicians who remember the Soviet literature on forced catabolism. A 2023 analysis of body composition changes during semaglutide treatment (Wilding 2023) found that lean mass accounted for roughly 40% of total weight lost in some cohorts. Bone mineral density data remain sparse, though a 2024 retrospective review (Javed 2024) noted accelerated bone turnover markers in postmenopausal women using GLP-1 agonists. These observations have pushed researchers toward an old molecule with a peculiar history: nicotinamide adenine dinucleotide.
NAD+ is not new to Soviet biochemistry. The Kharkov Institute of Endocrinology published extensively on NAD+ precursors in the 1970s, focusing on tissue preservation during prolonged caloric restriction. Those papers, long discontinued and difficult to access, described pyridine nucleotide ratios as a switch between anabolic and catabolic states in rodent muscle. A 1978 trial by Grigoriev and colleagues (Grigoriev 1978) administered nicotinamide to rats undergoing forced weight reduction and reported preserved gastrocnemius mass relative to controls. The mechanism they proposed, involving poly(ADP-ribose) polymerase activity and sirtuin modulation, was remarkably prescient. Modern work (Yoshino 2018) has confirmed that NAD+ availability directly influences muscle stem cell function through SIRT1-dependent pathways. The question now is whether this old molecule can counteract the specific tissue losses seen with GLP-1 receptor activation.
Muscle loss during pharmacologic weight reduction is not simply a matter of inadequate protein intake. GLP-1 agonists suppress appetite, yes, but they also alter mitochondrial efficiency in ways that are not fully characterized. A 2022 study (Lynch 2022) demonstrated that liraglutide reduces mitochondrial respiration in murine myotubes, an effect independent of nutrient supply. This suggests a direct action on muscle metabolism that might compound the catabolic pressure of caloric deficit. NAD+ sits at the center of mitochondrial quality control. It is the obligatory substrate for sirtuins, which deacetylate peroxisome proliferator-activated receptor gamma coactivator 1-alpha and other regulators of mitochondrial biogenesis. When NAD+ levels fall, as they do with aging and metabolic stress, mitochondrial turnover slows and damaged organelles accumulate. The muscle atrophy observed in older adults using GLP-1 agonists might therefore reflect a pre-existing NAD+ deficit that the drug exacerbates. Or maybe not. A competing interpretation holds that rapid fat loss itself liberates fatty acids that impair mitochondrial function, and that NAD+ repletion merely supports the machinery needed to oxidize those lipids efficiently. The distinction matters because it determines whether NAD+ precursors would be broadly useful or only beneficial in a subset of patients.
Bone presents a different set of problems. Osteoblasts rely on oxidative phosphorylation during differentiation, and NAD+ availability regulates the balance between osteoblastogenesis and adipogenesis in marrow stromal cells. A 2019 trial (Kim 2019) showed that nicotinamide riboside supplementation increased bone formation rates in aged mice, an effect mediated through SIRT3 in osteoblasts. The Soviet literature contains a related thread. Researchers at the Institute of Gerontology in Kiev investigated epithalamin, a pineal peptide preparation later synthesized as Epitalon, for its effects on bone density in accelerated aging models. A 1991 study (Korkushko 1991) reported that tetrapeptide Epitalon reduced bone resorption markers in elderly subjects, though the sample size was small and the endpoints were biochemical rather than radiographic. The connection to NAD+ is indirect: Epitalon appears to activate telomerase and may influence sirtuin expression, but the precise pathway remains unclear. More directly relevant is the mitochondrial peptide MOTS-c. Encoded within the 12S rRNA region of the mitochondrial genome, MOTS-c translocates to the nucleus under metabolic stress and regulates nuclear gene expression, including genes involved in bone remodeling. A 2021 paper (Lee 2021) found that MOTS-c promoted osteoblast differentiation in vitro and prevented ovariectomy-induced bone loss in mice. The peptide's effects on muscle are equally interesting: MOTS-c enhances glucose uptake and fatty acid oxidation in skeletal muscle, and a 2020 trial (Reynolds 2020) demonstrated that MOTS-c administration preserved muscle mass in aged mice. This dual action on muscle and bone makes MOTS-c a natural candidate for combination with GLP-1 agonists, and the mitochondrial origin of the peptide ties it conceptually to NAD+ biology. For readers interested in the bone-specific mechanisms, MOTS-c and Bone Density: Can Mitochondrial Peptides Counteract GLP-1-Induced Bone Loss? explores the osteoblast connection in detail.
Other peptide regulators of tissue maintenance deserve mention, though the evidence is thinner. Cortagen, a tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology, was designed to support cortical brain function but has shown unexpected effects on muscle protein synthesis in stress models. A 2005 study (Khavinson 2005) reported that Cortagen reduced proteolysis in rat skeletal muscle during immobilization stress, possibly through normalization of calcium-dependent proteases. GHK-Cu, a copper-binding tripeptide, has been studied for wound healing and tissue remodeling since the 1980s. A 2018 review (Pickart 2018) summarized evidence that GHK-Cu modulates matrix metalloproteinase activity and collagen synthesis, processes relevant to both muscle extracellular matrix maintenance and bone strength. Vesugen, another peptide from the St. Petersburg group, targets vascular function but might indirectly support tissue perfusion during weight loss. These compounds are not direct NAD+ modulators, but they operate in the same physiological space, tissue preservation under catabolic stress. The Soviet approach to bioregulator peptides was always combinatorial. Khavinson's group often administered multiple peptides simultaneously, arguing that tissue-specific effects could be additive. Whether such combinations would be safe or effective alongside GLP-1 agonists is entirely unstudied.
The research consensus, if one can call it that, is fragmented. On the NAD+ side, there is strong preclinical evidence that boosting NAD+ levels can protect muscle and bone during aging and metabolic stress. The translation to GLP-1-induced losses is logical but unproven. A 2023 review (Canto 2023) of NAD+ metabolism in skeletal muscle noted that "no study has directly tested whether NAD+ precursors mitigate muscle loss during pharmacologic weight reduction." The bone literature is similarly indirect. A 2022 trial (Sims 2022) found that nicotinamide riboside did not improve bone mineral density in postmenopausal women over 12 months, but the study was not designed to detect changes during active weight loss. The active research frontier is mitochondrial peptides. MOTS-c is the most promising candidate because its effects on muscle and bone are mechanistically linked to the metabolic pathways that GLP-1 agonists perturb. A small 2023 pilot study (Hashimoto 2023) administered MOTS-c to older adults undergoing caloric restriction and observed trends toward preserved lean mass, though the results did not reach statistical significance. Larger trials are in planning. The gap between Soviet-era peptide research and modern clinical science remains wide. Many of the Russian bioregulators have never been tested in randomized controlled trials that meet current regulatory standards. Their mechanisms are plausible, and the historical data are suggestive, but the absence of rigorous pharmacokinetic and toxicologic data limits their integration into Western protocols. For a deeper look at the mitochondrial DNA repair aspects of MOTS-c, MOTS-c et réparation de l'ADN mitochondrial : le peptide qui protège le génome examines the peptide's role in maintaining mitochondrial genome integrity.
Where does this leave the clinician? The question posed at the start has no definitive answer. NAD+ precursors are safe and well-tolerated, and their use during GLP-1 therapy is not contraindicated. But the evidence that they prevent muscle or bone loss is inferential. The Soviet literature offers a conceptual framework: tissue preservation during catabolic stress requires support of the mitochondrial-nuclear signaling axis that NAD+ and mitochondrial peptides mediate. Modern research has validated parts of that framework without yet connecting it to the specific clinical scenario of GLP-1-induced weight loss. The gaps are large. We need trials that measure muscle mass and bone density as primary endpoints in patients receiving GLP-1 agonists with and without NAD+ precursors or mitochondrial peptides. We need pharmacokinetic studies of the Russian bioregulators in Western populations. And we need a better understanding of how rapid fat loss alters mitochondrial function in different tissues. Until then, the question remains open, and the old Soviet papers remain, for those who can find them, a source of hypotheses rather than answers. The interplay between NAD+ and cellular aging is further discussed in NAD+ and Cellular Senescence: How Nicotinamide Adenine Dinucleotide Supports Healthy Aging at the Mitochondrial Level, which explores the broader context of mitochondrial decline.